Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, announced the publication of preclinical research in Science Advances that supports the use of engineered suppressor tRNAs for treating Duchenne muscular dystrophy (DMD). The paper, titled “Engineering suppressor tRNAs for effective treatment of Duchenne Muscular Dystrophy,” was conducted by scientists at Tevard Biosciences, Johns Hopkins University, MIT, and the Whitehead Institute for Biomedical Research. The research describes the development of an engineered suppressor tRNA gene therapy aimed at patients with DMD caused by nonsense mutations in the dystrophin gene. The full paper is available at https://doi.org/10.1126/sciadv.aeg3466.
DMD is a severe, progressive muscle-wasting disease caused by mutations in the dystrophin gene. Nonsense mutations, which introduce premature stop codons, account for a significant portion of DMD cases. These mutations halt the production of full-length dystrophin, a protein essential for muscle fiber integrity. Current therapeutic strategies for DMD have limitations, including poor delivery to muscle tissues and the need for mutation-specific approaches. The new research addresses these challenges by engineering suppressor tRNAs that can read through premature stop codons and restore protein translation.
In a preclinical DMD model, the engineered suppressor tRNA therapy restored physiological levels of full-length dystrophin, improved muscle strength and motor coordination, and was well tolerated. Critically, the engineered suppressor tRNAs targeted disease-causing nonsense mutations while leaving normal stop codons intact, demonstrating exquisite selectivity. This selectivity is crucial because indiscriminate readthrough of normal stop codons could lead to harmful off-target protein production. The ability to distinguish between premature and normal stop codons suggests a favorable safety profile and reduces the risk of unintended effects.
The implications of this announcement extend beyond DMD. By targeting nonsense mutations as a class, the suppressor tRNA platform has potential applications for other genetic diseases caused by premature termination codons. Tevard Biosciences is advancing a pipeline of programs spanning Duchenne muscular dystrophy, genetic cardiomyopathies, and neurological disorders, including epilepsies. This approach could offer a mutation-agnostic therapy, meaning it could treat patients regardless of the specific nonsense mutation they carry, simplifying treatment development and broadening patient eligibility.
For patients with DMD, the findings represent a potential new therapeutic avenue that addresses the root cause of the disease rather than just managing symptoms. If translated to humans, this therapy could slow or reverse muscle degeneration, improve quality of life, and extend survival. The collaboration between academic institutions and a biotechnology company underscores the growing momentum behind tRNA-based therapeutics. While further research and clinical trials are needed, the preclinical results provide a strong rationale for advancing this platform into human testing. Tevard Biosciences’ work exemplifies how innovative RNA technologies can tackle previously undruggable targets, offering hope for a broad range of genetic disorders.
